vs
因美纳（ILMN）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
因美纳的季度营收约是Royalty Pharma plc的1.9倍（$1.2B vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 28.8%，领先5.6%），因美纳同比增速更快（5.0% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -0.7%）
因美纳是总部位于美国加利福尼亚州圣迭戈的生物技术企业，成立于1998年4月，专注研发、生产及销售用于分析基因变异与生物功能的集成系统，产品及服务覆盖测序、基因分型、基因表达、蛋白质组学等领域，业务遍及全球超155个国家和地区。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ILMN vs RPRX — 直观对比
营收规模更大
ILMN
是对方的1.9倍
$622.0M
营收增速更快
ILMN
高出0.2%
4.8%
净利率更高
RPRX
高出5.6%
28.8%
两年增速更快
RPRX
近两年复合增速
-0.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $622.0M |
| 净利润 | $334.0M | $214.2M |
| 毛利率 | 65.5% | — |
| 营业利润率 | 17.4% | 62.4% |
| 净利率 | 28.8% | 34.4% |
| 营收同比 | 5.0% | 4.8% |
| 净利润同比 | 185.5% | 2.9% |
| 每股收益（稀释后） | $2.16 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ILMNRPRX
| Q4 25 | $1.2B | $622.0M | ||
| Q3 25 | — | $609.3M | ||
| Q2 25 | — | $578.7M | ||
| Q1 25 | — | $568.2M | ||
| Q4 24 | $1.1B | $593.6M | ||
| Q3 24 | $1.1B | $564.7M | ||
| Q2 24 | $1.1B | $537.3M | ||
| Q1 24 | $1.1B | $568.0M |
净利润ILMNRPRX
| Q4 25 | $334.0M | $214.2M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $30.2M | ||
| Q1 25 | — | $238.3M | ||
| Q4 24 | $186.0M | $208.2M | ||
| Q3 24 | $705.0M | $544.0M | ||
| Q2 24 | $-2.0B | $102.0M | ||
| Q1 24 | $-126.0M | $4.8M |
毛利率ILMNRPRX
| Q4 25 | 65.5% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 65.9% | — | ||
| Q3 24 | 69.0% | — | ||
| Q2 24 | 64.8% | — | ||
| Q1 24 | 62.0% | — |
营业利润率ILMNRPRX
| Q4 25 | 17.4% | 62.4% | ||
| Q3 25 | — | 70.1% | ||
| Q2 25 | — | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | 15.8% | 60.9% | ||
| Q3 24 | 68.6% | — | ||
| Q2 24 | -147.2% | 50.2% | ||
| Q1 24 | -10.3% | -13.0% |
净利率ILMNRPRX
| Q4 25 | 28.8% | 34.4% | ||
| Q3 25 | — | 47.3% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | 16.8% | 35.1% | ||
| Q3 24 | 65.3% | 96.3% | ||
| Q2 24 | -178.8% | 19.0% | ||
| Q1 24 | -11.7% | 0.8% |
每股收益（稀释后）ILMNRPRX
| Q4 25 | $2.16 | $0.49 | ||
| Q3 25 | — | $0.67 | ||
| Q2 25 | — | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | $1.16 | $0.46 | ||
| Q3 24 | $4.42 | $1.21 | ||
| Q2 24 | $-12.48 | $0.23 | ||
| Q1 24 | $-0.79 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6B | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $2.7B | $9.7B |
| 总资产 | $6.6B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ILMNRPRX
| Q4 25 | $1.6B | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $93.0M | $929.0M | ||
| Q3 24 | $70.0M | $950.1M | ||
| Q2 24 | $74.0M | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务ILMNRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益ILMNRPRX
| Q4 25 | $2.7B | $9.7B | ||
| Q3 25 | — | $9.6B | ||
| Q2 25 | — | $9.5B | ||
| Q1 25 | — | $9.8B | ||
| Q4 24 | $2.4B | $10.3B | ||
| Q3 24 | $2.1B | $10.3B | ||
| Q2 24 | $1.4B | $9.8B | ||
| Q1 24 | $5.7B | $9.9B |
总资产ILMNRPRX
| Q4 25 | $6.6B | $19.6B | ||
| Q3 25 | — | $19.3B | ||
| Q2 25 | — | $18.3B | ||
| Q1 25 | — | $17.6B | ||
| Q4 24 | $6.3B | $18.2B | ||
| Q3 24 | $6.0B | $18.0B | ||
| Q2 24 | $6.1B | $17.7B | ||
| Q1 24 | $10.0B | $16.1B |
负债/权益比ILMNRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $321.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $267.0M | — |
| 自由现金流率自由现金流/营收 | 23.0% | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 0.96× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $935.0M | — |
8季度趋势，按日历期对齐
经营现金流ILMNRPRX
| Q4 25 | $321.0M | $827.1M | ||
| Q3 25 | — | $702.6M | ||
| Q2 25 | — | $364.0M | ||
| Q1 25 | — | $596.1M | ||
| Q4 24 | $364.0M | $742.5M | ||
| Q3 24 | $316.0M | $703.6M | ||
| Q2 24 | $80.0M | $658.2M | ||
| Q1 24 | $77.0M | $664.6M |
自由现金流ILMNRPRX
| Q4 25 | $267.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $335.0M | — | ||
| Q3 24 | $284.0M | — | ||
| Q2 24 | $49.0M | — | ||
| Q1 24 | $41.0M | — |
自由现金流率ILMNRPRX
| Q4 25 | 23.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 30.3% | — | ||
| Q3 24 | 26.3% | — | ||
| Q2 24 | 4.4% | — | ||
| Q1 24 | 3.8% | — |
资本支出强度ILMNRPRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | 2.8% | — | ||
| Q1 24 | 3.3% | — |
现金转化率ILMNRPRX
| Q4 25 | 0.96× | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | 1.96× | 3.57× | ||
| Q3 24 | 0.45× | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ILMN
| Product revenue | $990.0M | 85% |
| Service and other revenue | $169.0M | 15% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
